REL-1017
Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials
Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders
Relmada Therapeutics Considers Strategic Alternatives Following Depression Drug Setbacks
Relmada Therapeutics, depression drug, REL-1017, strategic alternatives, sale, major depressive disorder, NMDA receptor blocker
Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017
Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development